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ABSTRACT
Background: The worldwide rise in the number of patients with chronic renal failure (CRF). Chronic Renal Failure is a 
major health problem resulting in considerable increase in mortality and morbidity, decreased quality of life and heavy cost of 
therapies. .
Objective: This study aims to evaluate the haematological parameters and iron status during monitoring of Chronic Renal 
Failure patients and to study the effects of subcutaneously and intravenously administered erythropoietin (EPO) in treating 
anaemia in Chronic Renal Failure patients. 
Methods: A retrospective record review study was conducted among the CRF patients treated at Hospital Pulau Pinang 
between 2005 and 2009. A total of 45 patients were randomly selected by using simple random sampling. The parameters were 
taken one to two weeks prior to EPO treatment and at 1 month and 3 months after EPO therapy was started. Data analyses 
were performed by using paired t test and independent t test via SPSS Version. 18.0.0.
Results: After one month post-EPO, there was a significant difference of mean serum iron between continuous ambulatory 
peritoneal dialysis (CAPD) and haemodialysis groups where the mean value of serum iron was higher in CAPD group. After 
three months post-EPO, there were significant differences of mean white blood cells and serum iron between the two groups.
Conclusions: Chronic renal failure patients undergoing dialysis responded to EPO treatment and subcutaneous EPO admin-
istration appeared to give more favourable results compared to intravenous EPO. 
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INTRODUCTION 
Chronic renal failure (CRF) is a condition in which the kidney func-
tion gradually declines and irreversible the destruction of kidney with a 
serious and also long term medical condition1). 
The worldwide rise in the number of patients with CRF is a major 
health problem resulting in considerable increase in mortality and mor-
bidity, decreased quality of life and heavy cost of therapies. Diabetes, 
hypertension, an older age and obesity are considered to be risk factors 
assicated with development of CRF2,3). Patients with CRF are often 
anaemic, have poor haemostasis, and may show leukocyte and platelet 
function abnormalities4). 
Anaemia is the most common problem faced in patients with CRF5). 
Observational studies in haemodialysis patients have found anaemia to 
be associated with higher mortality in populations in which the vast 
majority of patients had hemoglobin levels between 6 and 12 g/dl6-8). 
Associations of anaemia with hospitalization and resource utilization 
also have been reported9,10)
The prevalence of CKD and end-stage renal disease (ESRD) is 
increasing through the worldwide. The estimated prevalence of CKD in 
the US was 16.8% while in Asia the prevalence ranged from 12.1% to 
17.5%11-13). 
In Malaysia, the incidence and prevalence of patients with ESRD on 
dialysis had increased from 88 and 325 per million population (pmp) 
respectively in 2001 to 170 and 762 per million population respectively 
in 200914).
The growing number of ESRD places an enormous human, eco-
nomic and social burden on the healthcare system. In an economic eval-
uation among Ministry of Health, dialysis centers in Malaysia, the cost 
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of dialysis and erythropoietin was RM2,500 per month15) while com-
pared in the US, the cost of medical care was 1.7 times higher in 
patients with CKD stage 3 and 2.6 times higher in those with stage 4 
CKD compared with controls16,17). 
Many factors have been implicated in its pathogenesis, which 
include a markedly depressed erythropoiesis due to reduced erythropoi-
etin (EPO) production in the kidney18). Recombinant human erythropoie-
tin (rHuEPO) is one of the greatest advances in nephrological practice 
over the last decades. Before the advent of recombinant human erythro-
poietin, many patients with renal failure required repeated blood trans-
fusions in order to avoid the symptoms and complications of severe 
anaemia. Erythropoietin which is produced by recombinant DNA tech-
nology in mammalian cell is used in treating anaemia resulting from 
CRF19).
Recombinant human erythropoietin is inactivated by acid in the 
stomach, and therefore needs to be given parenterally. In the early hae-
modialysis clinical trials, patients were administered intravenous eryth-
ropoietin thrice weekly. Subsequently, the intraperitoneal, Subcutaneous 
and intradermal routes of administration were investigated20).
Many studies have compared the efficacy and dose requirement of 
erythropoietin administrated intravenously versus subcutaneously. Most 
suggest lower dose may be required if the subcutaneous route is used21). 
Considering the practicality of the subcutaneous route, it seems very 
likely that this is going to become the standard mode of EPO adminis-
tration.
Regular monitoring of patients physical vital signs as well as moni-
toring of laboratory parameters such as haematological parameters and 
iron status are done to evaluate the efficacy of erythropoietin are 
extremely important. 
This study was aimed to evaluate these haematological parameters 
and iron status during mnitoring of CRF patients, and to study the 
effects of subcutaneously and intravenously administered erythropoietin 
(EPO) in treating anaemia in CRF patients.
MATERIALS  AND  METHODS 
A retrospective record review study was conducted among the 
chronic renal failure patients treated at Hospital Pulau Pinang, Malaysia 
whose clinical records were available within the time frame between 
2005 and 2009. The participants were all chronic renal failure patients 
on erythropoietin treatment. Only patients who had completed records 
of all haematological parameters and iron status variables were included 
in the study. Patients who were given erythropoietin due to cancer or 
diseases other than CRF were excluded from the study. 
The calculation of sample size was performed with requirements for 
level of significance 0.05 and power of 80% using two means (paired) 
formula. The predetermined sample size was 45. The data was obtained 
from patients' clinical records in Nephrology Department from 
Haemodialysis and Continuous Ambulatory Peritoneal Dialysis (CAPD) 
units at Hospital Pulau Pinang. 
The total number of clinical records of chronic renal failure patients 
undergoing dialysis in Hospital Pulau Pinang was 237. This consisted of 
175 on CAPD and 62 on haemodialysis. The total number of clinical 
records of patients who were treated with recombinant human erythro-
poietin was 51 from haemodialysis unit and 148 from CAPD unit. A 
total of 45 patients who had complete haematological parameter and 
iron status were randomly selected by using simple random sampling: 
20 from CAPD unit and 25 in haemodialysis unit.
Patients on CAPD were treated with recombinant human erythro-
poietin (EPO) by subcutaneous injections, of doses in the range of 2 
000, 4 000, 8 000 and 12 000 IU/mL two to three times weekly. On the 
other hand, patients on haemodialysis received recombinant human 
erythropoietin (EPO) by intravenous route with a dose range of 2 000 ‒ 
4 000 IU/mL three times weekly.
The clinical records were reviewed by a single researcher and a data 
collection form was used to record all the information in the clinical 
records which included age, gender, diagnosis of the patients, type of 
erythropoietin treatment, and administration of erythropoietin and dose 
of the erythropoietin given. 
The haematological parameters with respective measurement units 
were also obtained from patients' clinical records which included hae-
moglobin (HB) g/dL, mean corpuscular volume (MCV) fL, mean cor-
puscular haemoglobin concentration (MCHC) g/dL, white blood cells 
(WBC) 103/μL, lymphocyte count 103/μL, platelet count 103/μL, serum 
iron μmol/L, serum ferritin g/dL and total iron biding capacity (TIBC) 
μmol/L. However, data for lymphocyte count was unavailable in 
patients’ clinical records, and were not included in the data analysis. 
These parameters were taken one to two weeks prior to EPO treatment 
(pre-EPO), and at 1 month and 3 months after EPO therapy was started 
(post-EPO). 
Ethical clearance was obtained from Clinical Research Center of 
Hospital Pulau Pinang, Research and Medical Research Ethics 
Committees in the Ministry of Health Malaysia and Research and Ethics 
Committee of Advanced Medical and Dental Institute, Universiti Sains 
Malaysia.
Table 1. Comparison of mean haematological parameters and iron 
status between pre and one month after EPO treatment in 
CAPD group of patients (n = 20)
Variables Pre-EPO 1 month  Mean diff  t-stata  p-value
  post-EPO (95% CI) (df)
 Mean (SD) Mean (SD)   
Haemoglobin 9.73  10.08  0.35  0.85  0.405
 (1.10) (1.58) (-1.21, 0.51) (19)
MCV 86.89  90.69  3.80  4.27  < 0.001*
 (4.67) (5.65) (1.94, 5.67) (19)
MCHC 32.60  32.33  -0.27  -1.13  0.269
 (0.10) (1.03) (-0.23, 0.77) (19)
WBC 7.82  7.02  -0.80  58.6  0.426
 (1.81) (5.65) (-0.86, 0.80) (19)
Lymphocyte  2.01  2.26  0.25  2.09  0.049
count (0.59) (0.73) (0.07, 0.51) (19)
Platelet count 283.20  252.40  -30.80  -2.78  0.012*
 (58.91) (39.49) (7.69, 53.91) (19)
Ferritin 746.80  651.92  94.90  -1.60  0.125
 (337.24) (370.59) (28.82, 218.57) (19)
Serum iron 13.77  13.02  -0.75  -0.40  0.691
 (7.64) (5.41) (-3.13, 4.63) (19)
TIBC  41.60  43.63  2.03  0.81  < 0.001*
 (11.66) (7.53) (-7.27, 3.19) (19)
aPaired t test was applied 
Table 2. Comparison of mean haematological parameters and iron 
status between pre and three month after EPO treatment 
in CAPD group of patients (n = 20)
Variables Pre-EPO 3 month  Mean diff  t-stata  p-value
  post-EPO (95% CI) (df)
 Mean (SD) Mean (SD)   
Haemoglobin 9.73  14.92  5.19  -0.23  0.234
 (1.10) (18.62) (-3.64, 14.02) (19)
MCV 86.89  87.68  0.79  0.23  0.818
 (4.67) (14.04) (-7.88, 6.29) (19)
MCHC 32.60  31.17  -1.43  -1.07  0.290
 (0.10) (6.05) (-1.43, 4.22) (19)
WBC 7.82  7.03  -0.79  -1.82  0.084
 (1.81) (1.79) (-1.17, 1.70) (19)
Lymphocyte  2.01  2.03  -0.20  0.21  0.840
count (0.59) (0.55) (-0.23, 0.18) (19)
Platelet count 283.20  230.24  -52.96  -3.96  0.001*
 (58.91) (75.62) (-80.90, -25.01) (19)
Ferritin 746.80  625.48  -121.30  -1.43  0.168
 (337.24) (355.30) (-298.2, 55.6) (19)
Serum iron 13.77  15.13  1.36  0.45  0.650
 (7.64) (9.70) (-7.68, 4.95) (19)
TIBC  41.60  44.57  2.97  1.20  0.244
 (11.66) (9.01) (-2.20, 8.15) (19)
aPaired t test was applied
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Statistical analysis
Statistical Program for Social Science Software (SPSS), version 
18.0.1, was used for data entry and data analysis. All the data were dou-
ble checked and cleaned to verify that the entire variables were properly 
documented and to detect any missing or erroneous values during data 
entry.
Exploration of data was then conducted to obtain descriptive statis-
tics. Paired t test was used to compare the mean values of the haemato-
logical parameters and iron status between pre and post EPO treatment 
within each CAPD and haemodialysis group of patients. Meanwhile, 
independent t test was used to compare the mean values of the haemato-
logical parameters and iron status between two groups for each of the 
measurements. 
RESULTS
A total of 20 patients in CAPD group were recruited in the study 
which consisted of 11 males and nine females aged ranging from 54 to 
58 years old. On the other hand, a total of 25 patients in haemodialysis 
group were included which comprised 13 males and 12 females with 
aged ranging from 44 to 46 years old. 
The result showed differences in mean MCV, lymphocyte count, 
platelet count and TIBC between pre-EPO and one month post-EPO 
levels in CAPD group of patients Table I. There were significant incre-
ments of mean MCV, TIBC and lymphocyte count values at one month 
post-EPO compared to pre-EPO levels. On the other hand, the mean of 
platelet count decreased at one month post-EPO. The result was consis-
tent for platelet count where there was a significant reduction of mean 
platelet count between pre-EPO and three months post-EPO in the same 
group of patients Table 2.
For haemodialysis group of patients, there was a significant differ-
ence in mean haemoglobin between pre-EPO and one month post-EPO 
(mean difference = 1.01; 95% CI: -1.65, -0.38; p = 0.030) Table 3. The 
result remained same for three months post-EPO where there was a sig-
nificant difference for haemoglobin between pre-EPO and three months 
post-EPO but not for other haematological parameters and iron status 
Table 4. 
Before EPO treatment was given, there were significant differences 
of mean MCV, MCHC and platelet count between CAPD and haemodi-
alysis groups of patients Table 5. The results show that the mean MCV 
was higher in haemodialysis group, while mean MCHC and platelet 
count were higher in CAPD group. After one month post-EPO, there 
was a significant difference of mean serum iron between these two 
groups where the mean value of serum iron was higher in CAPD group 
of patients Table 6. Meanwhile, after three months post-EPO, there 
were significant differences of mean white blood cells and serum iron 
between the two groups of patients Table 7. The mean white blood cell 
was higher in haemodialysis group and the mean serum iron was higher 
in CAPD group. 
Table 3. Comparison of mean haematological parameters and iron 
status between pre and one month after EPO treatment in 
haemodialysis group of patients (n = 25)
Variables Pre-EPO 1 month  Mean diff  t-stata  p-value
  post-EPO (95% CI) (df)
 Mean (SD) Mean (SD)   
Haemoglobin 9.34  10.35  1.01  3.31  0.030*
 (1.56) (1.54) (0.38, 1.65) (24)
MCV 91.56  91.12  -0.44  -5.69  0.575
 (8.46) (7.83) (-1.16, 2.05) (24)
MCHC 31.72  31.49  -0.22  -4.25  0.675
 (1.87) (2.48) (-0.86, 1.31) (24)
WBC 8.06  8.51  0.45  0.48  0.635
 (2.64) (5.40) (-2.37, 1.47) (24)
Platelet count 226.80  224.16  -2.64  -0.28  0.779
 (66.17) (64.75) (-16.60, 21.88) (24)
Ferritin 615.76  596.37  -19.37  -0.46  0.644
 (661.52) (619.07) (-66.20, 105.01) (24)
Serum iron 11.40  7.97  -3.43  -2.72  0.130
 (7.64) (5.07) (-6.06, 0.80) (24)
TIBC  41.83  39.12  -2.71  -1.48  0.156
 (11.25) (8.46) (-6.55, 1.12) (24)
aPaired t test was applied
Table 4. Comparison of mean haematological parameters and iron 
status between pre and three month after EPO treatment 
in haemodialysis group of patients (n = 25)
Variables Pre-EPO 3 month  Mean diff  t-stata  p-value
  post-EPO (95% CI) (df)
 Mean (SD) Mean (SD)   
Haemoglobin 9.34  11.22  1.88  5.08  < 0.001*
 (1.56) (1.45) (1.12, 2.65) (24)
MCV 91.56  90.22  -1.34  -1.55  0.132
 (8.46) (8.47) (-3.11, 0.43) (24)
MCHC 31.72  31.87  0.15  0.51  0.612
 (1.87) (1.98) (-0.76, 0.45) (24)
WBC 8.06  8.57  0.51  0.79  0.439
 (2.64) (2.83) (-1.85, 0.82) (23)
Platelet count 226.80  225.12  -1.68  -0.19  0.853
 (66.17) (61.29) (-16.80, 20.16) (24)
Ferritin 615.76  592.80  -22.96  -0.27 0.790
 (661.52) (894.64) (-152.86, 198.61) (24)
Serum iron 11.40  9.40  -2.56  -1.98  0.060*
 (7.64) (6.70) (-11.20, 5.23) (22)
TIBC  41.83  43.89  2.46  0.99  0.333
 (11.25) (12.24) (-7.63, 2.71) (20)
aPaired t test was applied
Table 5. Comparison of mean haematological parameters and iron status between two groups before EPO 
treatment
Variables CAPD  Haemodialysis  Mean diff (95% CI) t-stata (df) p-value
 (n = 20) (n = 25)
 Mean (SD) Mean (SD)   
Haemoglobin 9.73 (1.10) 9.34 (1.56) 0.39 (-0.44, 1.22) 0.94 (43) 0.350
MCV 86.89 (4.67) 91.56 (8.46) -4.67 (-8.93, -0.41) -2.21 (43) 0.032
MCHC 32.60 (0.10) 31.72 (1.87) 0.88 (0.03, 1.73) 2.10 (43) 0.042
WBC 7.82 (1.81) 8.06 (2.64) -0.24 (-1.64, 1.16) -0.35 (43) 0.731
Platelet count 283.20 (58.91) 226.80 (66.17) 56.40 (18.25, 94.55) 2.98 (43) 0.005*
Ferritin 746.80 (337.24) 615.76 (661.52) 131.04 (-197.28, 459.36) 0.80 (43) 0.425
Serum iron 13.77 (7.64) 11.40 (7.64) 2.37 (-2.25, 6.99) 1.03 (43) 0.307
TIBC  41.60 (11.66) 41.83 (11.25) -0.23 (-7.15, 6.69) -0.07 (43) 0.947
aIndependent t test was applied
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DISCUSSION
The results of this study showed that the haemoglobin level in the 
haemodialysis group of patients was found to be 9.34 (1.56) g/dl pre 
treatment and this increased to 10.35 (1.54) g/dl after one month and 
11.22 (1.45) g/dl after three months on EPO therapy. After three months 
on intravenous EPO, the haemoglobin level was increased by 1.88 g/dL. 
On the other hand, the haemoglobin level in CAPD group of patients 
increased by 5.19 g/dl after three months of subcutaneous EPO treat-
ment. However, these findings were not statistically significant and this 
could be due to the relatively small sample size.
Both groups of patients managed to achieve a target haemoglobin 
level of 11 to 12 g/dl. It is interesting to note that the rise in haemoglo-
bin was greater in the CAPD group compared to the haemodialysis 
group after three months post-EPO. This is in contrast to results of a 
study conducted in older Medicare enrollees by Synder JJ,et al., (2004) 
whereby patients who received peritoneal dialysis were substantially 
less likely to have initiated erythropoietin than patients who received 
haemodialysis. In both groups, the target haemoglobin level was 
achieved. The Haemoglobin level of the haemodialysis group was great-
er than that of the CAPD group22). 
It has long been believed that CAPD patients tend to be less anae-
mic than haemodialysis patients23,24). This study reported that the ferritin 
level reduced after treatment with recombinant human erythropoietin in 
both CAPD and haemodialysis groups. Similar result by another study 
showed that CAPD patients treated with rHuEPO was associated with a 
decrease in ferritin26).
The present study also revealed that subcutaneous rHuEPO was 
more effective in treating anaemia in CAPD patients compared to intra-
venous route of administration in haemodialysis patients. This was 
reported from the overall results of the parameters evaluated where 
those of the CAPD group showed higher changes compared to the hae-
modialysis group. An acceptable target haemoglobin concentration can 
be achieved with considerably lower dose erythropoietin of subcutane-
ous rHuEPO than those normally recommended.
A study by Besarab et al., (2002) in the United States, reported that 
erythropoietin is usually given intravenously to haemodialysis patients 
and subcutaneously to peritoneal dialysis patients. The subcutaneous 
route is believed to be more efficacious in terms of haemoglobin level 
achieved21). There are also other studies that suggested anaemia is less 
common and more sensitive to erythropoietin in CAPD patients than in 
haemodialysis patients, possibly because blood loss is less marked and 
residual renal function may be better preserved in patients who received 
peritoneal dialysis. Besid blood is usually drawn before a dialysis ses-
sion; as a result, haemoglobin is likely to be partly diluted25,26).
A decrease in erythropoietin response similar to our findings was 
reported in another study27). The study was restricted to older patients in 
the first year of dialysis therapy. It is unlikely those haemodialysis 
patients, on average, have more co-morbid conditions at the inception of 
dialysis therapy, which may well decrease erythropoietin responsive-
ness. 
On evaluating the iron status of patients, the present study showed a 
significant increase in the mean TIBC level of patients undergoing 
CAPD and after one month treated with rHuEPO. TIBC also increased 
by 2 μmol/L in the haemodialysis group after three months of treatment 
but it was not statistically significant. Mean MCV was increased in the 
CAPD group but reduced in the haemodialysis group. Serum iron 
showed a mild increase of 1.36 μmol/L in the CAPD group, while it 
decreased by 2.56 μmol/L in the haemodialysis group. Ferritin levels in 
both dialysis groups reduced post-treatment compared to pre-treatment 
levels, though this was not statistically significant. Iron deficiency is 
one of the most common complications in patients suffering from CRF 
and undergoing dialysis. 
The anaemia leads to severe impairment of quality of life and is 
associated with a decreased haemoglobin level and MCV concentration. 
The administration of erythropoietin leads to stimulation of the bone 
marrow production of red blood cells, which results in an increase in 
haemoglobin level, MCV, serum iron, serum ferritin and TIBC and 
improves the quality of life of patients. EPO therapy will reduce the 
exposure of patients to red blood cells transfusions to avoid the results 
of adverse effects of blood transfusion. The most important goals of 
erythropoietin treatment are avoidance or elimination of blood transfu-
sion and improved quality of life.
Table 6. Comparison of mean haematological parameters and iron status between two groups one month after 
EPO treatment
Variables CAPD  Haemodialysis  Mean diff (95% CI) t-stata (df) p-value
 (n = 20) (n = 25) 
 Mean (SD) Mean (SD)   
Haemoglobin 10.08 (1.58) 10.35 (1.54) -0.27 (-1.21, 0.67) 0.58 (43) 0.567
MCV 90.69 (5.65) 91.12 (7.83) -0.43 (-4.64, 3.78) -0.21 (43) 0.838
MCHC 32.33 (1.03) 31.49 (2.48) 0.84 (-0.36, 2.04) 1.42 (43) 0.164
WBC 7.02 (5.65) 8.51 (5.40) -1.49 (-4.82, 1.84) -0.90 (43) 0.373
Platelet count 252.40 (39.49) 224.16 (64.75) 28.24 (-5.06, 61.54) 1.71 (43) 0.094
Ferritin 651.92 (370.59) 596.37 (619.07) 55.55 (-261.48, 372.58) 0.35 (43) 0.726
Serum iron 13.02 (5.41) 7.97 (5.07) 5.05 (1.89, 8.21) 3.22 (43) 0.002*
TIBC  43.63 (7.53) 39.12 (8.46) 4.51 (-0.37, 9.39) 1.86 (43) 0.069
aIndependent t test was applied
Table 7. Comparison of mean haematological parameters and iron status between two groups three months 
after EPO treatment
Variables CAPD Haemodialysis  Mean diff (95% CI) t-stata (df) p-value
 (n = 20) (n = 25)
 Mean (SD) Mean (SD)
Haemoglobin 14.92 (18.62) 11.22 (1.45) 3.70 (-3.82, 11.22) 0.99 (43) 0.326
MCV 87.68 (14.04) 90.22 (8.47) -2.54 (-9.36, 4.28) -0.75 (43) 0.457
MCHC 31.17 (6.05) 31.87 (1.98) -0.70 (-3.29, 1.89) -0.54 (43) 0.589
WBC 7.03 (1.79) 8.57 (2.83) -1.54 (-3.01, -0.07) -2.12 (43) 0.040
Platelet count 230.24 (75.62) 225.12 (61.29) 5.12 (-36.02, 46.26) 0.25 (43) 0.803
Ferritin 625.48 (355.30) 592.80 (894.64) 32.68 (-396.19, 461.55) 0.15 (43) 0.879
Serum iron 15.13 (9.70) 9.40 (6.70) 5.73 (0.79, 10.67) 2.34 (43) 0.024*
TIBC  44.57 (9.01) 43.89 (12.24) 0.68 (-5.93, 7.29) 0.21 (43) 0.837
aIndependent t test was applied
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Low or decreased serum iron status may be a result of increased 
level of circulating cytokine capable of inducing macrophages of reticu-
loendothelial system that hold on iron which may lead to a decrease in 
the endogenous EPO production or decreased responsiveness of eryth-
roid precursor cells to endogenous or exogenous EPO. Various reasons 
could have caused the reduced platelet counts in both groups of patients 
in the present study. Some of these reasons may include platelet dys-
function which is common in CRF. Others may include uremia, heredi-
tary thrombocytopenia and drugs.
There were few limitations of the present study. Some data were 
missing from the clinical records of patients. This suggests proper docu-
mentation is very important. The short study period only allowed evalu-
ation of rHuEPO treatment up to three months. However, as patients are 
treated on a long term basis with rHuEPO, it would be useful to track 
their haemoglobin and iron status over a longer period of time. Other 
confounding factors that may affect haemoglobin and iron status includ-
ed patients’ diet, compliance to dietary supplement pills from hospital, 
other underlying chronic diseases such as hypertension, diabetes, blood 
loss during menstruation in women and blood loss due to other condi-
tions.
CONCLUSION
CRF patients undergoing dialysis respond to EPO treatment and 
Subcutaneous EPO administration and intravenous EPO. The haemodi-
alysis group was healthier than the CAPD group. However, other con-
founding factors need to be considered.
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